Xenogen Grants New Evaluation License For Its Unique, Patented Real-Time In Vivo
ALAMEDA, Calif., May 10 /PRNewswire/ – Xenogen Corporation, a leader and innovator in the field of real-time in vivo imaging, today announced it has entered into an evaluation licensing agreement with DuPont Pharmaceuticals, the worldwide pharmaceutical company. This evaluation license offers DuPont access to Xenogen's proprietary suite of technologies to assess their application in pre-clinical drug development studies. This alliance follows a number of other agreements with pharmaceutical and biotechnology companies who are currently using Xenogen's technology.
Xenogen's unique technology represents a novel approach to the biological assessment of new chemical entities (NCEs) – compounds that may eventually serve as the basis for beneficial therapies. Critical advantages offered by Xenogen's technology include providing higher quality data at earlier time points, thus allowing for better selection of drug development candidates. These advantages result in time and cost savings in drug development.
"Xenogen is pleased to enter into this alliance with DuPont Pharmaceuticals, a center of leading-edge research," said Pamela Reilly Contag, Ph.D., president and co-CEO of Xenogen Corporation. "It is our hope that Xenogen's technology will be of significant benefit to DuPont researchers as they seek to develop innovative new therapies."
About the Technology
Xenogen's patented real-time in vivo imaging technology enables the detection of fluorescent or bioluminescent cells (e.g., tumor cells and bacteria) inside intact living animals, allowing non-invasive visualization and tracking of the cells to monitor the effects of treatment with NCEs in vivo in real-time. The technology also provides researchers with a way to localize and follow the activation of selected genes in vivo in Xenogen's LPTATM light producing transgenic animals.
Real-time in vivo imaging offers pharmaceutical companies like DuPont a number of unique benefits to help increase the productivity of their drug development pipelines. Compared to traditional methods, this technology provides improved, more predictive data and thus a better selection process for drug development candidates. In addition, Xenogen's technology allows researchers to conduct assessments more rapidly and efficiently. The resulting reduction in labor costs, coupled with a reduction in the number of test animals needed, leads to significant overall cost savings.
Xenogen Corporation is a leader in the field of real-time in vivo imaging, providing the pharmaceutical industry with proprietary technologies, products and services that enable real-time in vivo monitoring to rapidly identify drug leads for successful clinical development. These technologies, unique to Xenogen, enable researchers to overcome barriers that have complicated biological assessment for many years. Xenogen's technology has attracted strong interest from a wide range of pharmaceutical companies worldwide. In addition to pharmaceutical development, the technology has broad applications in other fields, including toxicology and the chemical industry.
SOURCE Xenogen Corporation
VP & CFO - Xenogen Corporation
860 Atlantic Avenue
Alameda CA 94501